HC Wainwright Reaffirms Buy Rating for Imunon (NASDAQ:IMNN)

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They presently have a $14.00 target price on the stock.

Separately, D. Boral Capital restated a “buy” rating and set a $29.00 price objective on shares of Imunon in a report on Monday.

Imunon Trading Down 6.1 %

Shares of Imunon stock opened at $1.00 on Wednesday. The firm has a market capitalization of $14.62 million, a P/E ratio of -0.53 and a beta of 1.96. The business’s fifty day simple moving average is $0.90 and its 200 day simple moving average is $0.91. Imunon has a 12 month low of $0.64 and a 12 month high of $3.65.

Institutional Trading of Imunon

A hedge fund recently raised its stake in Imunon stock. Geode Capital Management LLC lifted its stake in Imunon, Inc. (NASDAQ:IMNN) by 10.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 139,505 shares of the company’s stock after acquiring an additional 13,570 shares during the period. Geode Capital Management LLC owned approximately 0.96% of Imunon worth $133,000 at the end of the most recent reporting period. Institutional investors own 4.47% of the company’s stock.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.